INTERIM REPORT JANUARY 1 – MARCH 31 , 2005

EXPANSION INTO NEW THERAPY AREAS. NEW SHARE ISSUE • Artimplant´s net sales for the period reached SEK 1.1 million (SEK 1.0 million) • Losses after tax was SEK 9.1 million (SEK 6.6 million) • The loss per share was SEK 0.23 (SEK 0.17) • ARTELON TMC Spacer was launched by Small Bone Innovations (Avanta Orthopaedics) at AAOS – American Academy of Orthopaedic Surgeons – in Washington DC • Artimplant expands into new product areas, Odontology and Craiomaxillofacial surgery and conducts a rights issue. Institutional investors have through guarantees and letters of intent committed to subscribe to shares corresponding to 92% of the issue

For more information, contact: Tord Lendau, CEO, +46 31 746 5600, +46 708 369 403, tord.lendau@artimplant.se